These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 14511401)

  • 1. Evaluation of novel antimouse VEGFR2 antibodies as potential antiangiogenic or vascular targeting agents for tumor therapy.
    Ran S; Huang X; Downes A; Thorpe PE
    Neoplasia; 2003; 5(4):297-307. PubMed ID: 14511401
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-angiogenic effects and regression of localized murine AML produced by anti-VEGF and anti-Flk-1 antibodies.
    Reichert F; Barak V; Tarshis M; Prindull G; Tarshis E; Ben-Ishay Z
    Eur J Haematol; 2005 Jul; 75(1):41-6. PubMed ID: 15946309
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A monoclonal antibody that blocks VEGF binding to VEGFR2 (KDR/Flk-1) inhibits vascular expression of Flk-1 and tumor growth in an orthotopic human breast cancer model.
    Zhang W; Ran S; Sambade M; Huang X; Thorpe PE
    Angiogenesis; 2002; 5(1-2):35-44. PubMed ID: 12549858
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antiangiogenic therapy of established tumors in human skin/severe combined immunodeficiency mouse chimeras by anti-endoglin (CD105) monoclonal antibodies, and synergy between anti-endoglin antibody and cyclophosphamide.
    Takahashi N; Haba A; Matsuno F; Seon BK
    Cancer Res; 2001 Nov; 61(21):7846-54. PubMed ID: 11691802
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
    Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C
    Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selective inhibition of vascular endothelial growth factor (VEGF) receptor 2 (KDR/Flk-1) activity by a monoclonal anti-VEGF antibody blocks tumor growth in mice.
    Brekken RA; Overholser JP; Stastny VA; Waltenberger J; Minna JD; Thorpe PE
    Cancer Res; 2000 Sep; 60(18):5117-24. PubMed ID: 11016638
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Monitoring response to anticancer therapy by targeting microbubbles to tumor vasculature.
    Korpanty G; Carbon JG; Grayburn PA; Fleming JB; Brekken RA
    Clin Cancer Res; 2007 Jan; 13(1):323-30. PubMed ID: 17200371
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of human leukemia in an animal model with human antibodies directed against vascular endothelial growth factor receptor 2. Correlation between antibody affinity and biological activity.
    Zhu Z; Hattori K; Zhang H; Jimenez X; Ludwig DL; Dias S; Kussie P; Koo H; Kim HJ; Lu D; Liu M; Tejada R; Friedrich M; Bohlen P; Witte L; Rafii S
    Leukemia; 2003 Mar; 17(3):604-11. PubMed ID: 12646950
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Angiogenesis and radiation response modulation after vascular endothelial growth factor receptor-2 (VEGFR2) blockade.
    Li J; Huang S; Armstrong EA; Fowler JF; Harari PM
    Int J Radiat Oncol Biol Phys; 2005 Aug; 62(5):1477-85. PubMed ID: 16029810
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel anti-denatured collagen humanized antibody D93 inhibits angiogenesis and tumor growth: An extracellular matrix-based therapeutic approach.
    Pernasetti F; Nickel J; Clark D; Baeuerle PA; Van Epps D; Freimark B
    Int J Oncol; 2006 Dec; 29(6):1371-9. PubMed ID: 17088974
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting tumor-associated endothelial cells: anti-VEGFR2 immunoliposomes mediate tumor vessel disruption and inhibit tumor growth.
    Wicki A; Rochlitz C; Orleth A; Ritschard R; Albrecht I; Herrmann R; Christofori G; Mamot C
    Clin Cancer Res; 2012 Jan; 18(2):454-64. PubMed ID: 22065082
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Human/mouse cross-reactive anti-VEGF receptor 2 recombinant antibodies selected from an immune b9 allotype rabbit antibody library.
    Popkov M; Jendreyko N; Gonzalez-Sapienza G; Mage RG; Rader C; Barbas CF
    J Immunol Methods; 2004 May; 288(1-2):149-64. PubMed ID: 15183093
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The structural basis for the function of two anti-VEGF receptor 2 antibodies.
    Franklin MC; Navarro EC; Wang Y; Patel S; Singh P; Zhang Y; Persaud K; Bari A; Griffith H; Shen L; Balderes P; Kussie P
    Structure; 2011 Aug; 19(8):1097-107. PubMed ID: 21827946
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-vascular endothelial growth factor receptor 2 antibody reduces tumorigenicity and metastasis in orthotopic prostate cancer xenografts via induction of endothelial cell apoptosis and reduction of endothelial cell matrix metalloproteinase type 9 production.
    Sweeney P; Karashima T; Kim SJ; Kedar D; Mian B; Huang S; Baker C; Fan Z; Hicklin DJ; Pettaway CA; Dinney CP
    Clin Cancer Res; 2002 Aug; 8(8):2714-24. PubMed ID: 12171905
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and antivascular effects of EphA2 reduction with an agonistic antibody in ovarian cancer.
    Landen CN; Lu C; Han LY; Coffman KT; Bruckheimer E; Halder J; Mangala LS; Merritt WM; Lin YG; Gao C; Schmandt R; Kamat AA; Li Y; Thaker P; Gershenson DM; Parikh NU; Gallick GE; Kinch MS; Sood AK
    J Natl Cancer Inst; 2006 Nov; 98(21):1558-70. PubMed ID: 17077358
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vascular endothelial growth factor is an in vivo survival factor for tumor endothelium in a murine model of colorectal carcinoma liver metastases.
    Bruns CJ; Liu W; Davis DW; Shaheen RM; McConkey DJ; Wilson MR; Bucana CD; Hicklin DJ; Ellis LM
    Cancer; 2000 Aug; 89(3):488-99. PubMed ID: 10931447
    [TBL] [Abstract][Full Text] [Related]  

  • 17. KDR/Flk-1 is a major regulator of vascular endothelial growth factor-induced tumor development and angiogenesis in murine hepatocellular carcinoma cells.
    Yoshiji H; Kuriyama S; Hicklin DJ; Huber J; Yoshii J; Miyamoto Y; Kawata M; Ikenaka Y; Nakatani T; Tsujinoue H; Fukui H
    Hepatology; 1999 Nov; 30(5):1179-86. PubMed ID: 10534339
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel dual inhibitors of vascular endothelial growth factor and VEGFR2 receptor.
    Nguyen JP; Frost CD; Lane ML; Skelton WP; Skelton M; Vesely DL
    Eur J Clin Invest; 2012 Oct; 42(10):1061-7. PubMed ID: 22703300
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vascular endothelial growth factor as a marker of tumor endothelium.
    Brekken RA; Huang X; King SW; Thorpe PE
    Cancer Res; 1998 May; 58(9):1952-9. PubMed ID: 9581838
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis and growth of several mouse and human tumors.
    Prewett M; Huber J; Li Y; Santiago A; O'Connor W; King K; Overholser J; Hooper A; Pytowski B; Witte L; Bohlen P; Hicklin DJ
    Cancer Res; 1999 Oct; 59(20):5209-18. PubMed ID: 10537299
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.